Arsenic Trioxide S.K. is indicated for induction of remission, and consolidation in adult patients with:
- Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10×1000µl incombination with all-trans-retinoic acid (ATRA)
- Relapsed/refractory acute promyelocytic leukaemia (APL)(Previous treatment should have included a retinoid and chemotherapy) characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.
The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.
**Disclaimer:
The images and designs presented on this website are for illustrative purposes only. Actual products may differ from those shown, including variations in color, packaging design, wording, or other visual features. The company assumes no responsibility for any such discrepancies and does not undertake to update the website to reflect changes in the actual product.
*** Disclaimer
The information provided herein is not intended as medical advice and must not be relied upon for diagnosis, treatment, or the provision of medical care. It does not replace the official prescribing/patient leaflet or consultation with a qualified healthcare professional. Before any use, always review the official physician/patient leaflet and consult a licensed physician. The company assumes no responsibility or liability for any reliance placed on the information presented on this page.
